September 1st, 2022Salt Lake City - Fluidx Medical announces completion of trial enrollment for its novel embolic device, GPX. In this multi-center trial, GPX was used to treat a variety of primary and metastatic tumors, renal adenoma tumors, and a range of other arterial and venous applications.
“We are pleased to announce the enrollment of the...
August 10th, 2022Fluidx Medical’s GPX Embolic Material Yields Promising Results for Oncology Uses
Fluidx Medical disclosed study results examining extent of vessel filling using the GPX Embolic Device compared to microspheres, a common treatment for many types of tumors.
Embolization is a procedure in which arterial or venous blood supply to an...
March 9th, 2022Innovative Embolic Device by Fluidx Medical Used Successfully in a Variety of Complex Cancer Cases
Salt Lake City – As part of an ongoing multi-center study, Fluidx Medical released additional information on treating tumors including a highly vascularized metastatic renal cell carcinoma with the GPX Embolic Device.
“We were very...
February 2nd, 2022Fluidx Medical Reports Initial Research on First-of-its-Kind Embolic Agent with Intermediate Radiopacity
Fluidx Medical Technology announces results of its GPX-Clear Embolic Device in-vivo research which uses the base GPX technology and incorporates an intermediate term radiopacity agent.
“Our initial in-vivo work with GPX-Clear...
January 20th, 2022Fluidx Medical’s Novel Embolic Device Demonstrates Repeated Success in Treating Complex Tumors
Fluidx Medical’s GPX Embolic Device was used to effectively devascularize a large tumor with multiple feeding vessels as part of a multi-center clinical trial.
“This could have been a challenging case since it involved a large renal...
December 1st, 2021Novel Oncology Embolic Device financing supports prospective, clinical trials and market entry
Fluidx Medical Technology, a privately held medical device company founded to develop GPX, an innovative embolic material, and other technologies today announced the oversubscribed closing of the first tranche of its Series A financing...
November 2nd, 2021Fluidx Medical’s GPX Embolic Device Releases Initial Results for Oncology Drug Delivery
Fluidx Medical Technology announced that a next-generation, doxorubicin-loaded GPX Embolic Device was featured at the recent Symposium on Clinical Interventional Oncology (CIO) Conference highlighting the technology’s potential for oncology drug...
August 24th, 2021Fluidx Medical’s GPX™ Embolic Device Use for Tumor Treatments Chosen for “BEST of GEST” Embolization Program at the Annual GEST Meeting
Fluidx Medical Technology’s GPX Embolic Device was selected for a Global Embolization Oncology Symposium Technologies (“GEST”) “BEST of GEST” session highlighting the technology’s...
March 30th, 2021New Embolic Device Blocks Vessels Feeding Malignant Tumors
Fluidx Medical’s GPX™ Embolic Device Demonstrates Versatility and Control in Oncology Clinical Use
Fluidx Medical Technology, Inc. released details on clinical use of their GPX Embolic Device for blocking flow to small microvasculature and large tumor feeding...
February 2nd, 2021GPX Embolic Device Showcased at Leipzig Interventional Course (LINC) for Interventional Oncology Embolizations
Fluidx Medical Technology announced GPX Embolic Device first patient use cases were presented at the Leipzig Interventional Course (LINC) in Leipzig, Germany...
Novel Interventional Oncology Embolization Device Successfully Used in Trans-Radial Access Procedures for Tumor Devascularization
November 24, 2020 – Fluidx Medical Technology reported successful patient use of the GPX Embolic Device to therapeutically devascularize, or block blood supply to, a tumor.
“We are impressed with the...
